Efficiency of Two Dimensional High Definition vs Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery

Sponsor
Corporacion Parc Tauli (Other)
Overall Status
Completed
CT.gov ID
NCT01498354
Collaborator
(none)
36
1
2
18
2

Study Details

Study Description

Brief Summary

Introduction: The usual surgical technique for large adenomatous tumors and rectal cancer is anterior resection of the rectum or abdominoperineal resection. These techniques are associated with high mortality and morbidity and with genitourinary dysfunctions.

To solve these problems, transanal endoscopic microsurgery (TEM) was designed. Through its 3-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge. It is associated with minimal morbidity and has few repercussions for anal continence.

The use of 2-D high definition cameras and screens obtains images of a similar quality to 3-D images. This means that from the surgical point of view the procedure known as TEO (transanal endoscopic operation) seems as practicable as classic TEM.

Main aim: To assess the effectiveness of 2-D high definition vision systems (TEO) versus conventional 3-D (TEM) in endoscopic surgery of rectal tumors, with respect to surgical facility, postoperative morbidity, quality of the surgical specimens, and cost.

Design: Prospective, controlled, randomized study of the efficacy of the use of 2-D high definition endoscopic systems versus 3-D (TEM) in transanal endoscopic surgery.

Disease studied: Rectal adenomas and adenocarcinomas "in situ" suitable for local surgery.

Main variable evaluated: Cost per procedure assuming similar surgical efficacy and equal postoperative morbidity.

Study population and total number of patients: Patients diagnosed with rectal tumor treated with curative intent (rectal adenomas and adenocarcinomas "in situ"). The total sample calculated for the trial was 36 patients, 18 in each group (TEO and TEM).

Timing and expected finish date: After approval by the CEIC, the expected date for the inclusion of the first patient was August 2010. The study is expected to last 18-24 months.

Condition or Disease Intervention/Treatment Phase
  • Procedure: 2-D high definition vision systems, transanal endoscopic operation (TEO)
  • Procedure: Transanal endoscopic microsurgery (TEM)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparing the Efficiency of Two Dimensional High Definition (TEO) Versus Three Dimensional (TEM) Endoscopic Systems in Transanal Endoscopic Surgery; a Prospective Control Trial
Study Start Date :
Aug 1, 2010
Actual Primary Completion Date :
Oct 1, 2010
Actual Study Completion Date :
Feb 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: 2-D high definition TEO (transanal endoscopic operation)

Procedure: 2-D high definition vision systems, transanal endoscopic operation (TEO)
Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge

Active Comparator: Transanal endoscopic microsurgery (TEM)

Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge

Procedure: Transanal endoscopic microsurgery (TEM)
Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge

Outcome Measures

Primary Outcome Measures

  1. Cost per procedure assuming similar surgical efficacy and equal postoperative morbidity [30 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients of either sex older than 18 years

  • Rectal tumor identified as rectal adenoma by multifocal biopsy using colonoscopy, with endorectal ultrasound and magnetic resonance imaging findings of non-invasive tumor.

  • Size of the tumor between 2 and 6 cm in maximum diameter.

  • Tumor location, lower edge at least 2 cm from the anal verge, and upper edge at least 15 cm from the anal verge.

  • ASA score more than III.

  • intervention was performed under general anesthesia

Exclusion Criteria:
  • Invasive adenocarcinoma shown in the final pathology study. "in situ" or intraepithelial adenocarcinomas are not excluded .

  • Pregnant patients

  • Patients with liver cirrhosis or blood dyscrasia.

  • Patients who can not be administered under general anesthesia.

  • Patients on antiplatelet or anticoagulation therapy who have not been properly prepared for surgery.

  • Presence of two or more transanal endoscopic excisions in the same procedure.

  • Informed consent not signed.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Corporacion Sanitaria Universitaria Parc Tauli Sabadell Barcelona Spain 08208

Sponsors and Collaborators

  • Corporacion Parc Tauli

Investigators

  • Principal Investigator: Xavier Serra-Aracil, MD, Corporacion Sanitaria Universitaria Parc Tauli

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xavier Serra-Aracil, Medical Doctor, Corporacion Parc Tauli
ClinicalTrials.gov Identifier:
NCT01498354
Other Study ID Numbers:
  • TEO-TEM-2010-01
First Posted:
Dec 23, 2011
Last Update Posted:
Apr 18, 2019
Last Verified:
Apr 1, 2019
Keywords provided by Xavier Serra-Aracil, Medical Doctor, Corporacion Parc Tauli
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 18, 2019